VABOMERE is supplied as a white to light yellow sterile powder for constitution in single-dose, clear glass vials that contain 2 grams of VABOMERE. Each vial contains 1 gram of meropenem (equivalent to 1.14 grams of meropenem trihydrate), 1 gram of vaborbactam, and 0.575 gram of sodium carbonate.
ONE BOX is ONE DAY of treatment.*
VABOMERE 4 g (2 g meropenem and 2 g vaborbactam)
Each vial contains VABOMERE 2 g (1 g meropenem and 1 g vaborbactam) for injection and is supplied in a box of 6 vials.
Typical full course of daily treatment for patients with eGFR ≥50 mL/min/1.73 m2. Additional dosing information for patients with renal impairment can be found in the Dosing section of this website.
VABOMERE is a wholesaler-stocked product. Please use standard ordering procedure through your wholesaler. If product is not available at your wholesaler, your wholesaler can easily coordinate a drop shipment via Next Day Saver from a Melinta primary distribution provider by calling your wholesaler‘s customer service number listed below.
The Centers for Medicare & Medicaid Services (CMS) has approved VABOMERE for NTAP status. Medicare will now provide an add-on payment for VABOMERE of up to $8,316 per qualifying case to Inpatient Prospective Payment System (IPPS)-participating acute care hospitals. This add-on payment will be incremental to the MS-DRG reimbursement for qualifying Medicare inpatient cases.
*NTAP maximum payment for FY2019 (ending September 30, 2019) is 50% or up to $5,544 per admission.
Under the IPPS system, costs are retrospectively reviewed on an annual basis in order to set the prospective DRG payment rates. Depending on the time of the introduction of the new technology, it can take 2 to 3 years before its cost is recognized in the recalibration of MS-DRG payment rates.3
In place of an ICD-10-PCS procedure code, cases of VABOMERE eligible for FY2020 NTAP will be paid with the following 11-digit NDC code in data element LIN03 of the 837i Health Care Claim Institutional form: 65293000901 or 70842012001.
The 11-digit NDC is required, and dashes are not allowed on the claim when inserting the code.
The content of the guides made available on this website are general in nature, strictly for informational purposes only, and do not cover all situations or all payers’ policies and guidance. The information provided in these guides were obtained from third-party sources and are subject to change without notice as a result of changes in reimbursement laws, regulations, rules, policies, and payment amounts. These guides are not intended to provide clinical practice guidelines.
Melinta Therapeutics, Inc. (Melinta) cannot guarantee, and is not responsible for, the payment of any claim. The coding, coverage, and payment of VABOMERE may vary by payer, plan, patient, and setting of care. Coding determinations and analysis should always be independently researched and assessed. For more information, please check with individual payers for specific coding, coverage, and payment requirements. It is the sole responsibility of the healthcare provider to code properly and to ensure the accuracy of all claims submitted for reimbursement. Additionally, as a prerequisite for submitting a claim, the provider is responsible for ensuring that all services are medically necessary and properly supported in the patient’s medical records.
Melinta specifically disclaims liability or responsibility for the results or consequences of any actions taken in reliance on information in provided in these guides.
References: 1. VABOMERE [package insert]: Melinta Therapeutics, Inc. 2. Centers for Medicare & Medicaid Services. Medicare Program: Hospital inpatient prospective payment systems for acute care hospitals and the long term care hospital prospective payment system and policy changes and fiscal year 2020 rates; quality reporting requirements for specific providers; Medicare and Medicaid promoting interoperability programs requirements for eligible hospitals and critical access hospitals [unpublished]. Fed Regist. https://federalregister.gov/d/2019-16762. Accessed August 8, 2019. 3. Additional payment for new medical services and technologies: general provisions, 42 CFR § 412.87 (2010). https://www.govinfo.gov/content/pkg/CFR-2010-title42-vol2/pdf/CFR-2010-title42-vol2-sec412-87.pdf. Published October 10, 2010. Accessed May 22, 2019. 4. Centers for Medicare & Medicaid Services. New medical services and new technologies. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.html. Published December 3, 2018. Accessed May 22, 2019.
VABOMERE® (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
VABOMERE is contraindicated in patients with known hypersensitivity to any components of VABOMERE (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.
The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE were headache, phlebitis/infusion site reactions, and diarrhea.Please see full Prescribing Information.